Evidence map›Paper›PMID 41811969›Full record

Observational studyNephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association2026

Renal blood flow and progression to kidney failure in ADPKD.

Kristen L Nowak, Timothy P Copeland, Elaine Ku, Mark J Sarnak, Zhiying You, Berenice Gitomer, Kaleab Z Abebe, Kyongtae T Bae, Arlene Chapman, Ronald Perrone and 4 more

Registry-linked trialAbstract readObservational Study
In one paragraph

Observational study in Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00283686 (HALT Progression of Polycystic Kidney Disease Study A), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00283686 phase3completednot on this map

HALT Progression of Polycystic Kidney Disease Study A

TypeinterventionalSponsorNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Ran2006 to 2014Enrolled558ConditionsKidney, PolycysticArmsLisinopril, Telmisartan, Placebo, Standard Blood Pressure Control, Low Blood Pressure Control
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Kristen L NowakDivision of Renal Diseases and Hypertension, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
Timothy P CopelandDivision of Nephrology, Department of Medicine, University of California-San Francisco, San Francisco, CA, USA.
Elaine KuDivision of Nephrology, Department of Medicine, University of California-San Francisco, San Francisco, CA, USA.
Mark J SarnakDivision of Nephrology, Tufts Medical Center, Boston, MA, USA.
Zhiying YouDivision of Renal Diseases and Hypertension, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
Berenice GitomerDivision of Renal Diseases and Hypertension, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
Kaleab Z AbebeDivision of General Internal Medicine, Department of Medicine, and Center for Biostatistics and Qualitative Methodology, University of Pittsburgh, Pittsburgh, PA, USA.
Kyongtae T BaeDepartment of Diagnostic Radiology, Li Ka Shing Faculty of Medicine, University of Hong Kong, Pok Fu Lam, Hong Kong.
Arlene ChapmanSection of Nephrology, Department of Medicine, University of Chicago, Chicago, IL, USA.
Ronald PerroneDivision of Nephrology, Tufts Medical Center, Boston, MA, USA.ORCID 0000-0002-4963-1132
Frederic F Rahbari-OskouiRenal Division, Department of Medicine, Emory University, Atlanta, GA, USA.
Vicente TorresDivision of Nephrology and Hypertension, Mayo Clinic, Rochester, MN, USA.
Alan S L YuDivision of Nephrology and Hypertension, Department of Internal Medicine, University of Kansas Medical Center, Kansas City, KS, USA.
Michel ChoncholDivision of Renal Diseases and Hypertension, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.

Funding

Acute declines in kidney function during blood pressure interventions in CKDR01DK121904 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI KU, ELAINE, SARNAK, MARK J · 2020 to 2023
$2.9M
Inspiratory muscle strength training for lowering systolic blood pressure in midlife and older adults with chronic kidney diseaseR01DK130266 · NIDDK · UNIVERSITY OF COLORADO DENVER · PI CHONCHOL, MICHEL BENJAMIN, NOWAK, KRISTEN LYNN · 2021 to 2025
$2.8M
Daily Caloric Restriction in Overweight and Obese Adults with ADPKDR01DK129259 · NIDDK · UNIVERSITY OF COLORADO DENVER · PI NOWAK, KRISTEN LYNN · 2021 to 2025
$2.7M
Advancing ADPKD Treatment with GLP-1RA: A Study of Glucagon-Like Peptide-1 Receptor Agonists' Efficacy, Safety, and MechanismR01DK138915 · NIDDK · UNIVERSITY OF COLORADO DENVER · PI Petter Bjornstad, Kristen Lynn Nowak · 2024 to 2026
$2.0M
NIDDK NIH HHS R01 DK121904NIDDK NIH HHS R01 DK129259NIDDK NIH HHS R01DK129259NIDDK NIH HHS R01 DK130266NIDDK NIH HHS R01 DK138915NIDDK NIH HHS R01DK138915NIH HHSZell Family Foundation
6 · The paper itself

Abstract

backgroundA decrease in renal blood flow (RBF) precedes estimated glomerular filtration rate (eGFR) decline among patients with autosomal dominant polycystic kidney disease (ADPKD) and inversely associates with disease severity and progression. However, it is unknown whether RBF independently predicts progression to kidney failure in patients with ADPKD.

methodsA total of 379 participants with early-stage ADPKD (mean age 36.6 ± 8.5 years; eGFR: 92.9 ± 17.1 ml/min/1.73 m2) who participated in the Halt Progression of Polycystic Kidney Disease Study A (HALT PKD A; NCT00283686) with baseline RBF (phase contrast magnetic resonance imaging) data were included in the primary analysis. Kaplan-Meier survival analysis and multivariate Cox proportional hazard models were used to determine the association of baseline RBF as a continuous and categorical variable with kidney failure risk (during the HALT study and subsequently linked to the US Renal Data System) over a median follow-up period of 13.1 years (interquartile range 7.5-14.5) (primary outcome). All-cause mortality was also considered as a competing risk (Fine and Gray method). The associations of RBF with eGFR slope and the change in height-adjusted total kidney volume (∆htTKV) were evaluated with linear and logistic regression models.

resultsThe kidney failure incidence rate was the highest among those with the lowest RBF tertile {1.90 [95% confidence interval (CI) 1.31-2.78] versus 0.34 [95% CI 0.14-0.83] events/100 person-years in tertile 3}. In the fully adjusted model, the lowest RBF tertile was associated with a higher risk of progression to kidney failure [hazard ratio (HR) 3.19 (95% CI 1.05-9.67] versus the highest tertile]. The association of RBF with kidney failure risk was slightly attenuated in adjusted models. All associations remained similar when considering death as a competing risk [HR 0.82 (95% CI 0.67-1.00) per 100 ml/min/1.73 m2 higher RBF]. Higher RBF was associated with a slower eGFR decline and lower odds of rapid annual ∆htTKV.

conclusionsLower baseline RBF independently associates with a greater risk of progression to kidney failure in early-stage patients with ADPKD.

Indexed as

Polycystic Kidney, Autosomal DominantRenal CirculationRenal InsufficiencyAdultClinical Trials, Phase III as TopicDisease ProgressionFemaleFollow-Up StudiesGlomerular Filtration RateHumansKidney Function TestsMaleMiddle AgedMulticenter Studies as TopicPrognosisRandomized Controlled Trials as TopicADPKDepidemiologykidney failurerenal blood flow

Identifiers

PMID41811969
PMCPMC13224814

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.